Acorah Software Products - Accounts Production 15.0.600 false true 28 February 2023 1 March 2022 false 1 March 2023 31 December 2023 31 December 2023 12437885 Dr Andreas Halner Mr Bradley Wilson Dr Jian Rui Liu Mr Marcus Delano East Mr Zhixin Qiao iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12437885 2023-02-28 12437885 2023-12-31 12437885 2023-03-01 2023-12-31 12437885 frs-core:CurrentFinancialInstruments 2023-12-31 12437885 frs-core:ComputerEquipment 2023-12-31 12437885 frs-core:ComputerEquipment 2023-03-01 2023-12-31 12437885 frs-core:ComputerEquipment 2023-02-28 12437885 frs-core:PlantMachinery 2023-12-31 12437885 frs-core:PlantMachinery 2023-03-01 2023-12-31 12437885 frs-core:PlantMachinery 2023-02-28 12437885 frs-core:SharePremium 2023-12-31 12437885 frs-core:ShareCapital 2023-12-31 12437885 frs-core:RetainedEarningsAccumulatedLosses 2023-12-31 12437885 frs-bus:PrivateLimitedCompanyLtd 2023-03-01 2023-12-31 12437885 frs-bus:FilletedAccounts 2023-03-01 2023-12-31 12437885 frs-bus:SmallEntities 2023-03-01 2023-12-31 12437885 frs-bus:AuditExempt-NoAccountantsReport 2023-03-01 2023-12-31 12437885 frs-bus:SmallCompaniesRegimeForAccounts 2023-03-01 2023-12-31 12437885 frs-bus:Director1 2023-03-01 2023-12-31 12437885 frs-bus:Director2 2023-03-01 2023-12-31 12437885 frs-bus:Director3 2023-03-01 2023-12-31 12437885 frs-bus:Director4 2023-03-01 2023-12-31 12437885 frs-bus:Director5 2023-03-01 2023-12-31 12437885 frs-countries:EnglandWales 2023-03-01 2023-12-31 12437885 2022-02-28 12437885 2023-02-28 12437885 2022-03-01 2023-02-28 12437885 frs-core:CurrentFinancialInstruments 2023-02-28 12437885 frs-core:SharePremium 2023-02-28 12437885 frs-core:ShareCapital 2023-02-28 12437885 frs-core:RetainedEarningsAccumulatedLosses 2023-02-28
Registered number: 12437885
Oxford Cancer Analytics Ltd
Unaudited Financial Statements
For the Period 1 March 2023 to 31 December 2023
Unaudited Financial Statements
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 12437885
31 December 2023 28 February 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 3 278,234 141,074
278,234 141,074
CURRENT ASSETS
Debtors 4 1,395 1,901
Investments 5 991,583 -
Cash at bank and in hand 751,725 2,969,557
1,744,703 2,971,458
Creditors: Amounts Falling Due Within One Year 6 (14,685 ) (18,656 )
NET CURRENT ASSETS (LIABILITIES) 1,730,018 2,952,802
TOTAL ASSETS LESS CURRENT LIABILITIES 2,008,252 3,093,876
NET ASSETS 2,008,252 3,093,876
CAPITAL AND RESERVES
Called up share capital 7 161 161
Share premium account 4,272,518 4,272,518
Profit and Loss Account (2,264,427 ) (1,178,803 )
SHAREHOLDERS' FUNDS 2,008,252 3,093,876
Page 1
Page 2
For the period ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Dr Andreas Halner
Director
9 August 2024
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. Accounting Policies
1.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
1.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Lab Equipment 25% straight line
Computer Equipment 25% straight line
1.3. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
2. Average Number of Employees
Average number of employees, including directors, during the year was as follows: 11 (2023: 9)
11 9
3. Tangible Assets
Lab Equipment Computer Equipment Total
£ £ £
Cost
As at 1 March 2023 145,693 3,428 149,121
Additions 215,808 - 215,808
As at 31 December 2023 361,501 3,428 364,929
Depreciation
As at 1 March 2023 7,682 365 8,047
Provided during the period 77,791 857 78,648
As at 31 December 2023 85,473 1,222 86,695
...CONTINUED
Page 3
Page 4
Net Book Value
As at 31 December 2023 276,028 2,206 278,234
As at 1 March 2023 138,011 3,063 141,074
4. Debtors
31 December 2023 28 February 2023
£ £
Due within one year
Other debtors 747 -
Net wages 648 1,901
1,395 1,901
5. Current Asset Investments
31 December 2023 28 February 2023
£ £
Short term deposits 991,583 -
991,583 -
6. Creditors: Amounts Falling Due Within One Year
31 December 2023 28 February 2023
£ £
Other taxes and social security 14,673 18,644
Directors' loan accounts 12 12
14,685 18,656
7. Share Capital
31 December 2023 28 February 2023
£ £
Allotted, Called up and fully paid 161 161
8. General Information
Oxford Cancer Analytics Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12437885 . The registered office is Bioescalator Innovation Building, Building 696, Old Campus Road, Roosevelt Drive, Headington, Oxford, OX3 7FZ.
Page 4